Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis

11/16/2021 | 09:27am EST

NEWARK, Calif. - Protagonist Therapeutics (Nasdaq: PTGX) ('Protagonist' or 'the Company') announced results from a Phase 2a study in which rusfertide, an investigational new drug, is being evaluated for the treatment of hereditary hemochromatosis (HH). HH is a genetic disorder arising from a deficiency or dysregulation of the natural hormone hepcidin, a condition which causes the body to absorb too much iron. The clinical data from the study were presented in an oral presentation at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD).

'Despite its prevalence, no drug therapies have been developed to date for the treatment of hereditary hemochromatosis,' said Kris V. Kowdley, M.D., Director of Liver Institute Northwest, Professor at the Elson S. Floyd College of Medicine at Washington State University, an author of the ACG Guidelines for HH, and the study's principal investigator. 'I'm encouraged by the efforts Protagonist has undertaken in this area of iron overload diseases, and specifically by the Phase 2 data that demonstrates rusfertide's therapeutic effect by several different measures, including pharmacodynamic effects, reduction in phlebotomy requirements, stabilization of liver iron content, and possible improvements in quality-of-life measures. Hereditary hemochromatosis is characterized by low levels of hepcidin, with variability of severity in clinical manifestations across different patient sub-populations. Rusfertide has the potential to offer a treatment option for patients in whom phlebotomy may be difficult or contraindicated.'

'Rusfertide has the potential to be the first-in-class drug therapy for an HH indication,' said Dinesh Patel, Ph.D., President and Chief Executive Officer of Protagonist. 'After polycythemia vera, this marks a second indication where rusfertide has demonstrated a positive clinical proof-of-concept, thereby signaling a broader potential utility to address unmet needs of patients in these diseases. The study results announced at AASLD will serve as an important foundation for the next steps that we will determine in consultation with key clinical investigators and regulatory agencies. Going forward, our focus will be on proving rusfertide's potential to address unmet medical needs in specific subpopulations of HH.'

Study Design and Summary of Results:

The study was an open-label multicenter Phase 2 study in 16 patients that was designed to evaluate the safety and efficacy of rusfertide as a treatment for patients with HH. The requirement for, and frequency of, therapeutic phlebotomies, a key endpoint of the study, was statistically significant: rusfertide-treated patients had 0.009 phlebotomies per month during the study compared to 0.28 phlebotomies per month pre-study (p

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about PROTAGONIST THERAPEUTICS, INC.
01/04/C O R R E C T I O N -- Protagonist Therapeutics, Inc./
PR
2021INSIDER SELL : Protagonist Therapeutics
MT
2021Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data
CI
2021Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summi..
PR
2021Protagonist Therapeutics Picks PN-235 for Mid-Stage Trials in Multiple Indications
MT
2021Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Cl..
PR
2021Protagonist Therapeutics Announces Selection of Oral Peptide PN-235 into Phase 2 Clinic..
CI
2021Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use ..
AQ
2021Protagonist Therapeutics Announces 'Positive Data' for Rusfertide as Possible Hereditar..
MT
2021JMP Securities Adjusts Price Target on Protagonist Therapeutics to $70 From $60, Keeps ..
MT
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 23,8 M - -
Net income 2021 -127 M - -
Net cash 2021 248 M - -
P/E ratio 2021 -12,6x
Yield 2021 -
Capitalization 1 636 M 1 636 M -
EV / Sales 2021 58,2x
EV / Sales 2022 57,5x
Nbr of Employees 116
Free-Float 98,9%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 34,27 $
Average target price 59,00 $
Spread / Average Target 72,2%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Donald A. Kalkofen Chief Financial Officer
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.1.14%1 651
MODERNA, INC.-26.53%75 661
LONZA GROUP AG-15.05%52 427
IQVIA HOLDINGS INC.-14.11%46 293
SEAGEN INC.-15.72%23 824
ICON PUBLIC LIMITED COMPANY-17.86%20 707